Yi Shuhua, Yan Yuting, Xiong Wenjie, Lv Rui, Yu Zhen, Liu Wei, Liu Enbin, Li Heng, Liu Huimin, Li Zengjun, An Gang, Xu Yan, Ru Kun, Zou Dehui, Qiu Lugui
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China.
Oncotarget. 2017 Oct 19;8(58):98757-98770. doi: 10.18632/oncotarget.21931. eCollection 2017 Nov 17.
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell neoplasm with hepatitis virus supposed to involve in the pathogenesis. The characteristics of SMZL derived from Caucasia population and high hepatitis C virus (HCV) infection region have been widely investigated, but few was reported in the Eastern population with HBV prevalent region. We analyzed the clinical characteristics, cytogenetic aberrations and prognostic factors in 160 SMZL patients from China. 25 patients (16%) were HBsAg-positive and 54 (34%) patients with resolved HBV infection. IGH gene usage was analyzed in 39 patients. The preferential usages of IGHV genes were IGHV1-2 (26%), followed by IGHV4-34 (18%) and IGHV2-70 (10%). The patients with HBV infection presented biased IGHV-D-J rearrangements and mutational status. Using three independent factors hemoglobin level, HBsAg positivity and complex karyotype, we developed a new hierarchical prognostic model, which showed a better c-index than the previously reported IIL and HPLL scoring systems in SMZL. In conclusion, SMZL in HBV prevalent region have unique clinical and biological characteristics and new prognostic scoring model should be adopted in this population.
脾边缘区淋巴瘤(SMZL)是一种罕见的惰性B细胞肿瘤,推测肝炎病毒参与其发病机制。源自高加索人群和丙型肝炎病毒(HCV)高感染地区的SMZL特征已得到广泛研究,但在乙型肝炎病毒(HBV)流行地区的东方人群中报道较少。我们分析了160例来自中国的SMZL患者的临床特征、细胞遗传学异常和预后因素。25例患者(16%)HBsAg阳性,54例患者(34%)有HBV感染康复史。对39例患者分析了IGH基因使用情况。IGHV基因的优先使用情况为IGHV1-2(26%),其次是IGHV4-34(18%)和IGHV2-70(10%)。HBV感染患者呈现IGHV-D-J重排和突变状态偏倚。利用血红蛋白水平、HBsAg阳性和复杂核型这三个独立因素,我们建立了一种新的分层预后模型,在SMZL中该模型的c指数比先前报道的IIL和HPLL评分系统更好。总之,HBV流行地区的SMZL具有独特的临床和生物学特征,该人群应采用新的预后评分模型。